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Background: First-line antiretroviral therapy (ART) regimen choices have evolved over the past 15 
years in South Africa. Many patients develop HIV drug resistance mutations when they fail first-line 
ART. The effect of different drug regimens and other patient related factors on drug resistant 
mutations selected at first line failure are not well characterised in Southern Africa with its 
predominantly subtype C epidemic. 
 
Objectives: To characterize HIV resistance mutations in patients failing first-line ART in the private 
sector in Southern Africa, and risk factors associated with resistance and particular resistance 
mutations. 
 
Methods: This was a retrospective observational study linking two databases. One database was that 
of the Aid for AIDS (AfA) disease management programme (for clinical and ART regimen data) and 
the other was that of Lancet Laboratories where HIV genotypic sequence data were stored. Variables 
included in analyses were age, gender, province, WHO stage at time of resistance testing (HIVDR), 
duration of ART at HIVDR, prior monotherapy or dual therapy, viral load and CD4 count prior to 
starting ART, viral load and CD4 count at HIVDR, duration that the viral load was >400 copies/ml 
prior to HIVDR and the HIV subtype. Data on patients who had a resistance test between 2008 and 
2014 while failing first-line ART was extracted from these databases. Fisher’s exact test and Chi-
squared test were used to analyse categorical variables and Wilcoxon rank sum test for continuous 
variables. For multivariate analyses, logistic regression models were used. 
 
Results: Patients who registered with AfA between 1998 and 2013 and had a resistance test 
performed  whilst experiencing viral failure on a non-nucleoside reverse transcriptase inhibitor 
(NNRTI) regimen with no history of prior failure on a protease inhibitor (PI) regimen were included. 
265 (95.3%) patients had a reverse transcriptase mutation of any kind, 253 (91%) had an NNRTI 
mutation and 246 (88.5%) had a nucleoside reverse transcriptase inhibitor (NRTI) mutation (n=278). 
The commonest mutation was the M184V mutation (80.6%), 44.2% had at least one thymidine 
analogue mutation (TAM) and 42.1% had the K103N/S mutation. Notably there was a median of 18 
months during which the viral load was not suppressed prior to the resistance tests, which likely 
contributed to the high prevalence of mutations. A total of 83 (29.9%) patients were found to have the 
K65R mutation, 72 of these patients were on tenofovir (TDF) at the time of resistance testing 
demonstrating the strong association between TDF and the K65R mutation.  
 
Conclusions: The mutational patterns observed in our study and their prevalence were similar to 
those noted in previous studies done within the region’s public sector. There was a high prevalence of 
the K65R mutation in patients failing TDF-containing regimens. A longer duration on ART and 










Antiretroviral therapy resistance and studies of first-line resistance reported from sub-Saharan 
Africa 
 
The Human Immunodeficiency Virus (HIV) epidemic and antiretroviral therapy (ART) 
 
The spread of HIV has resulted in over 36.9 million people living with HIV worldwide by the end of 2014, 
93% of whom were adults(1,2). By June 2015 a total of 15.8 million people infected with HIV were 
accessing anti-retroviral therapy (ART)(2). The greatest burden of disease is carried by sub-Saharan Africa 
where 71% of individuals with HIV reside (1). Globally, there has been a 35% decrease in new HIV 
infections since 2000, a 42% decrease in AIDS-related deaths since the peak in 2004 and an 84% increase in 
the access to ART since 2010(2). South Africa (SA) is by far the country with the most individuals living 
with HIV with over 6.8 million individuals estimated to be infected(3). Since 2000, there has been a rapid 
scale-up of ART in sub-Saharan Africa. An estimated 3 million individuals are now receiving ART in South 
Africa(3), which is the highest number globally and puts the country at the greatest risk for the development 
of resistance to ART. The ART regimens provided have undergone several changes as the knowledge of 
individual drug characteristics and side effects has evolved. In resource-limited settings ART options to date 
have been limited, however, with the development of cheaper ART drugs, over time more options are 
becoming available.  As a consequence of ART scale-up, this has predictably been accompanied by 
increasing drug resistance in individuals infected with HIV. Understanding the frequency and patterns of 
drug resistance will inform treatment and programmatic decisions regarding drug options. This review 
provides a brief introduction to relevant HIV virology, ART drugs, drug resistance mechanisms and a 
literature review of studies that reported ART resistance in patients who failed first-line ART in sub-Saharan 
Africa. Figure 1 represents the worldwide distribution of the various HIV subtypes and displays the 












HIV is a human retrovirus that belongs to the lentivirus family(5). There are two genetically distinct types of 
HIV, namely, HIV type 1 (HIV–1) and HIV type 2 (HIV–2). HIV–1 is the predominant type and is found 
throughout the world(4).  HIV-2 is less virulent and mainly seen in West Africa. HIV-1 can be further sub 
classified into M, N, O and P(4). The M subgroup is responsible for most infections worldwide and is 
divided into 9 clades (A, B, C, D, F, G, H, J and K(4). Subtype C is the most prevalent in sub-Saharan 
Africa and South Africa. HIV-2 is sub classified into groups A through to G(4). 
 
The HIV-1 virus is surrounded by a lipid envelope that is derived from the host cell membrane(5). Within 
the core of the virus are several key proteins, genes and enzymes(5). These include p24 which is described 
as the major capsid protein, the nucleocapsid proteins p7/p9, two copies of genomic RNA and three viral 
enzymes namely; protease, reverse transcriptase and integrase(5).  
 
The HIV–1 RNA genome contains several genes including the pol, gag and env genes(5). The pol and gag 
genes are translated into large precursor proteins that are cleaved into more mature proteins by the protease 
enzyme which is targeted by protease inhibitors(5).  
 
HIV infects CD4 T-cells by the binding of its surface protein gp-120 to the CD4 receptor and co-receptors 
CCR5 or CXCR4(4,5).  This attachment results in a conformation change and uncoating of the virion with 
penetration of the gp-41 transmembrane protein through the plasma membrane of the CD4 T cell(4,5). This 
results in subsequent entry of the virion into the cellular cytoplasm of the CD4 T cell(4,5). Its single-
stranded viral RNA is then reverse transcribed, by the viral reverse transcriptase enzyme into 
complementary DNA (cDNA)(5).  Thereafter double stranded DNA (dsDNA) is generated and this viral 
dsDNA is transferred into the nucleus of the cell by the viral integrase protein(5).  The viral integrase also 
cleavages the host DNA and allows for the viral cDNA to be integrated into the host DNA(5).  Once 
integrated into the host DNA the viral DNA is replicated by the host, thus, allowing for the viral proteins to 
be produced(5).  The viral proteins are assembled in the cytoplasm and packaged into immature virions(5).  
These immature virions bud out of the cell and mature through cleaving of viral polyproteins by the HIV 









ART drugs: adherence and resistance 
 
Antiretrovirals have been developed to target the viral proteins, namely, reverse transcriptase, integrase and 
protease.  NRTIs (nucleoside reverse transcriptase inhibitors), NNRTIs (non-nucleoside reverse 
transcriptase inhibitors) are the main first-line ART drugs used in SA and inhibit the reverse transcriptase 
(RT) enzyme. Protease inhibitors (PI’s) inhibit protease enzyme that is essential for formation of infectious 
virions and integrase inhibitors inhibit viral DNA integration into the host cell chromosome. Newer and 
investigational drug classes have other targets (e.g. entry inhibitors, capsid inhibitors).  
 
NRTIs resemble natural nucleotide building blocks of DNA and are therefore added to the developing strand 
of cDNA thereby inhibiting reverse transcription of the viral RNA into cDNA. NNRTIs bind to the 
hydrophobic pocket on the reverse transcriptase enzyme thereby inhibiting the viral RNA from binding to 
the RT enzyme.  
 
In sub-Saharan Africa first-line ART typically comprises of two NRTIs and 1 NNRTI. The most commonly 
used NRTIs are tenofovir (TDF), zidovudine (ZDV) or stavudine (D4T) in combination with lamivudine 
(3TC) or emtricitabine (FTC) together with either efavirenz (EFV) or nevirapine (NVP). Boosted protease 
inhibitors such as lopinavir/ritonavir are used in second–line therapy. When there is evidence to suggest 
ongoing viral replication (viral load > 1000 copies/ml) in spite of adherence to ART, it is defined as 
virological failure. Reasons for treatment failure include primary resistance (4) and drug toxicity causing 
poor adherence(6). 
 
Adherence is an important determinant of whether an individual will develop resistance to their drug 
regimen. Adherence between 70 – 90% has been thought of as being a driver of drug resistance mutations 
but Parienti et al showed that in individuals with low to moderate adherence, sustained interruption played a 
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more important role in the development of resistance mutations(7,8). Treatment interruptions may result 
from logistical or transport problems in resource limited settings(9); and side effects may result in poor 
adherence to a particular drug(10). Bangsberg et al note that some infected individuals experience a decline 
of adherence over an extended period after all HIV symptoms have resolved(11). Such patterns of poor 
adherence result in effective inadvertent monotherapy, because certain drugs have a longer half-life 
(especially the NNRTIs), creating selection pressure for drug-resistant mutant sub-populations of virus (2). 
Not all individuals experiencing treatment failure develop resistance and the treatment failure may still be 
corrected with improved adherence: in the PASER cohort 29% of patients failing first-line ART had wild–
type virus (12).  
 
Toxicity of the ART drugs is an important reason individuals may struggle with adherence and may result in 
them stopping their medication altogether. Ammassari et al showed that 30% of infected individuals  
experienced moderate to severe symptoms whilst on ART and this was significantly associated with 
adherence (13). Side effects vary between drugs and duration on ART and can range from hypersensitivity 
reactions to lipodystrophy and mitochondrial toxicity. 
 
Mechanisms of ART drug resistance 
 
On a genetic level drug resistance emerges due to single or multiple base changes in the HIV genes 
encoding for the amino acid sequence of an ART drug target. As a result there is a decreased affinity of the 
drug for its binding domain on that protein, in the case of NNRTIs and PIs. (6,14). The mechanism for NRTI 
resistance is either excision or discrimination (of nucleotide building blocks in DNA transcription), and this 
depends on the individual mutation.  
 
A classic example of a mutation that would affect NRTIs is the M184V mutation commonly associated with 
resistance to lamivudine and emtricitabine: methionine is replaced by valine at the 184 position of the RT 
enzyme.  
 
The type of mutation that develops is determined by the class of drugs and the duration of the regimen to 
which the infected individual is exposed (6). Each drug-resistant mutant can be present within the viral 
population prior to ART exposure but is outnumbered by the “wild type” virus(6). Poor adherence or 
interruptions result in “selection pressure” and the multiplication of resistant virus. This is further 
compounded by the poor “proofreading” capacity of the RT enzyme (6).  
 
In the South African guidelines the infected individual is said to be experiencing virological failure if the 
viral load is > 1000 copies/ml on two consecutive occasions (done 6-12 weeks apart) 24 weeks after the 
commencement of ART(15). Which mutation develops first is usually dependent on the genetic barrier of 
the drugs within the regimen,  NNRTIs and lamivudine have the lowest barrier(6). Therefore an individual 
experiencing treatment failure on the first-line regimen of tenofovir/emtricitabine/efavirenz will typically 
develop M184V and K103N mutations.  These initial mutations are followed by more NNRTI mutations. 
K65R may occur if they are taking tenofovir. Thymidine analogue mutations (TAMS) occur if the individual 
is taking AZT, three or more TAMs are needed to significantly decrease susceptibility to several NRTIs(6). 
Interestingly, K65R and TAM mutations exhibit a negative association and have been shown to 
phenotypically antagonize each other(16). In other words they do not often occur together and if occurring 
together the expected resistance profile present towards certain ART drugs decreases (16). Other NRTI 
mutations which cause wide cross-class resistance are the Q151M and the T69 insertion(15,17). The usage 
of triple NRTI ART regimens increased the likelihood for the accumulation of TAMs. In the DART trial 
55% of patients on triple NRTI therapy developed TAMs by 24 weeks(18). Triple NRTI regimens are no 
longer considered standard of care.  
 
Much of our understanding regarding HIV resistance has been developed in those infected with HIV-1 
subtype B virus in the United States and Europe and extrapolated to HIV-1 subtype C virus which is the 
predominant subtype in the Southern Africa and India. There is therefore a need to increase the knowledge 




Literature review of studies reporting ART drug resistance in sub-Saharan Africa 
 
The aim of this section of the literature review was to:  
 
• Characterize and compare studies conducted in sub-Saharan Africa with the aim to describe the 
commonest mutational patterns observed in individuals experiencing failure on first-line ART. 
• Describe primary resistance to first-line ART in this setting.  
• Describe the impact of virological monitoring on the development of resistance compared to the use 
of clinical and immunological monitoring criteria.  
• Discuss the prevalence of the K65R mutation and its impact on the choice of second-line therapy.  
• Discuss the impact of prior single–dose nevirapine on the development of resistance.  
• Describe baseline characteristics that contribute to the development of resistance and whether they 
influence the type of resistance pattern that develops.  
 
The role of drug resistance testing after first-line treatment failure was previously intensely debated. 
However, two recent clinical trials have shown that a more extensive mutational pattern at NNRTI-based 
first-line failure was not associated with poorer virological outcomes on second-line that included 
lopinavir/ritonavir. Indeed in these studies those with more extensive resistance at first-line failure were 
more likely to achieve virological suppression on second line ART (19,20). This evidence justifies the 
approach of following standardized treatment regimen sequencing without resistance testing as laid out in 
the WHO treatment guidelines (6). There may be a role for resistance testing at first-line failure to 
distinguish those patients with resistance versus those with non-adherence. However, in SA HIV drug 
resistance testing is generally preserved for individuals experiencing treatment failure on a second-line 
regimen who have demonstrated good compliance, to determine the best choice of third-line ART regimen. 
However, in many countries in sub-Saharan Africa resistance testing even for this indication is unaffordable 
and unavailable.  Studies have been undertaken comparing treatment efficacy of boosted PI’s in combination 
with either NRTI’s or raltegravir as part of second-line therapy without resistance testing: raltegravir has 
been shown to be similar to 2 NRTIs in terms of virological outcomes and side effects (19,20). Therefore the 
efficacy of boosted PIs with NRTIs (even if they are compromised by cross-resistance) argues against the 
use of genotyping in this clinical context.   
 
The question of outcomes with genotype guided therapy compared with standardized therapy was studied by 
Lessells et al(21). In this study in which standardized treatment recommendations were compared to the 
guidance ultimately obtained from genotyping, in patients failing first line ART it was found that 71.9% of 
patients were receiving the appropriate therapy with a standardized approach compared with what would 
have been prescribed using the recommendation obtained from the specialist physician who interpreted the 
genotype results. 26% of patients were found to have genotype-guided treatment recommendations that 
differed from the standardized therapy after treatment failure on first-line ART. Thus there appears to be 
some potential benefit from genotyping in this setting but this has to be weighed against the cost that has to 
be borne by the resource limited public sector(21). Cost benefit studies regarding genotyping have 
unfortunately mainly been limited to the United States and Europe with studies finding genotyping as being 
a cost effective practice that is beneficial to their respective health systems (22,23). Genotyping may be cost 
effective compared with the conventional approach of empirically switching to a subsequent generation of 
ART and that is in the case of resistance to second-line ART and switching to third-line therapy(24). It was 
suggested that the cost of genotyping was outweighed by the cost of switching a patient to expensive third-
line therapy which may be unnecessary if the patient is still treatment sensitive. Their health systems and 
population demographics however differ from ours therefore the results likely do not translate to our clinical 
setting with its resource constrains and very large numbers of patients. 
 
Primary or transmitted drug resistance needs to be considered as a cause of first-line ART failure, especially 
with the high HIV transmission rates in sub-Saharan Africa and large numbers on ART. Hosseinipour et al 
in a WHO drug resistance survey across 12 countries noted baseline resistance in 4,8% (2007) of patients 
starting first-line therapy and by 2010 it had risen to 6.8% and the increase was driven by NNRTI–
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associated mutations(12).  In the South African context Manasa et al. looked at the trend of primary HIV 
resistance over a period of ten years between 2000 and 2010 and noted that the prevalence of primary HIV 
resistance remained relatively low at less than 5% and there was no evidence to suggest an increase in the 
trend over the ten year period(25). By 2016 Steegen et al reported primary resistance in 9% of ART naïve 
individuals confirming a rise in the prevalence of primary resistance and underscoring the argument for 
genotype screening of ART-naïve individuals should this become affordable in the future(26). A slight 
deviation above the norm was noted in 2002, of 6,7%, but thereafter the levels remained consistently below 
5%(25). With widespread ongoing transmission of the virus in sub-Saharan Africa, primary resistance 
cannot be ignored and its impact for patients affected can mean ART failure despite good adherence. 
Genotyping, pre-ART initiation, and its impact on treatment outcomes has not been reviewed in our clinical 
setting but has some potential benefits as noted by Oette et al where it was revealed that initiation of ART 
guided by resistance testing for patients with primary resistance resulted in similar ART efficacy to patients 
being treated who had the wild–type virus(27). This strategy is unlikely to be affordable in sub-Saharan 
African countries. 
 
The resistance profile that develops in a particular individual and the impact it will have on second- and 
third-line ART has been shown to be determined by a number of factors. One of the factors determining 
what the resistance profile that develops at a cohort level is the method of treatment monitoring. 
Hosseinipour et al observed that when using clinical criteria such as the WHO staging and immunological 
parameters such as the CD4 count to monitor treatment response, this increased patients’ susceptibility to 
the development of not only a higher number of resistance mutations but these patients also develop 
mutations associated with pan–nucleoside resistance(17). 17% of the patients observed to have ART failure 
in this study had complex mutational patterns that would likely substantially diminish second-line therapy 
NRTI effectiveness when the clinical and immunological criteria were used to determine whether a patient 
was failing first-line therapy(17). The mutations of interest included the Q151M complex(17). This is in 
sharp contrast to the results of a study conducted by Wallis et al that monitored a cohort of patients 
receiving ART enrolled in the “CIPRA – SA safeguard the household study”(15). These patients were 
monitored by doing HIV viral load measurements 12 weekly and virological failure was defined as having a 
viral load >1000 copies/ml or not reducing the viral load by at least log 1.5 at week 12 of treatment(15). 
Complex mutational patterns were not observed as frequently: thymidine analogue mutations were seen in 
about 1% of the cohort and Q151M was not observed(15). The main factors here appear to be the method of 
monitoring (viral load monitoring detects failure sooner than CD4 monitoring) and the increased frequency 
with which these patients were being monitored compared to Hosseinpours’ cohort where it was noted that 
the average time spent on ART at the time of genotyping was about 36.5 months (17). This underscores the 
value of standardized, scheduled viral load monitoring as opposed to the use of clinical and immunological 
parameters to track a patient’s response to ART.  
 
With the phasing out of stavudine as part of first-line therapy due to its severe mitochondrial toxicities 
tenofovir has become part of standard first-line ART in South Africa. While providing a better side effect 
profile these two drugs share an ability to select out NRTI mutational patterns which may create challenges 
in the selection of NRTIs in second-line therapy. Tang et al showed that failure on stavudine can produce 
mutational patterns that result in TDF and AZT cross-resistance although it was found that the K65R or 
K70E mutation that impair TDF efficacy occurred in 5.3% of patients failing therapy and TAMs or Q151M 
which hamper AZT activity occurred in 22% of individuals(28). This review revealed that TDF was more 
likely to retain antiviral activity following stavudine failure than AZT (28). In another study done in 
Gugulethu, Cape Town, 9% of patients who had a resistance test after failing a first-line stavudine regimen 
had K65R (29). With the move towards TDF as part of the fixed drug combination regimen that includes 
emtricitabine and efavirenz in first-line there is a growing concern about the emergence of the K65R 
mutation and the rates at which this mutation arises in patients on tenofovir containing therapy(30–32) . 
Sunpath et al in a retrospective study of a cohort of patients failing TDF based regimens infected with HIV 
subtype C showed a very high rate for the selection of K65R (69.7%) - a much higher rate than that 
observed for stavudine in the review by Tang et al(33). With K65R susceptibility to AZT remains, but great 
challenges emerge when the patient has comorbidities that preclude AZT use. Some reassurance can be 
taken from the fact that K65R tended to occur in the absence of TAMs likely due to an antagonistic 
relationship between the two types of mutations(33). Although the change from stavudine to TDF has been 
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justified in that the side effect profile of the latter is more acceptable therefore decreasing the likelihood of 
defaulting medication due to poor tolerance, one concern about TDF is that it may more rapidly become 
resistant when a patient fails first-line ART. Doualla–Bell et al showed that the K65R mutation can be 
selected for by TDF-based ART within 12 weeks of therapy commencement (34). 
 
Single–dose nevirapine (sd-NVP) provided to pregnant women to prevent mother to child transmission of 
HIV–1 virus was common practice for many years. Data showing that the development of NNRTI resistance 
in this population is fairly consistent. Cunningham and colleagues revealed an NNRTI mutation prevalence 
of approximately 15% at 6 – 8 weeks after mothers  were given nevirapine to prevent MTCT (35). The 
impact that this has on later first-line ART and its effect on the further development of resistance has been 
studied. Wallis et al looked at women enrolled in the CIPRA–SA study to evaluate the emergence of 
complex mutational patterns in patients failing first–line ART. Of the women failing first-line ART a greater 
proportion had prior exposure to single dose nevirapine (39% vs. 28%)(15). Other studies have shown that 
these patients are more likely to fail nevirapine-based ART and there is associated mortality in these 
patients(36). Lockman et al demonstrated this in a study in which 241 women with prior exposure to single–
dose nevirapine were either started on nevirapine containing combination ART or lopinavir/ritonavir-based 
ART. More women started on nevirapine based ART reached the primary end point of the study which 
included virological failure or death (26% vs 8%)(36). Boltz et al compared the end points of virologic 
failure or death in women that had NVP related mutations at study entry with a prior history of single–dose 
nevirapine and without a history of single-dose nevirapine started on NVP based combination ART(37). 
Forty-one percent of women in the group with prior exposure to sd-NVP reached the primary endpoints 
compared with 21% in the group without prior exposure to sd-NVP (37).  Interestingly there is evidence to 
suggest that the nevirapine mutations “fade” beyond a period of 12 months(38). Lockmans’ study showed 
that ritonavir-boosted lopinavir based therapy lost its advantage over nevirapine as the interval since single–
dose nevirapine treatment and the commencement of ART increased(36).  Therefore it may be fair to 
conclude that prior use of single–dose nevirapine has an effect on the choice of future first-line ART though 
the effect is greatest within the first 12 months. The use of this strategy is now no longer advised, but there 
are women who had previous single-dose nevirapine who will still need to start ART. Thus the impact of 
single-dose nevirapine still needs to be considered. 
 
Nevirapine not only causes NNRTI associated mutations of concern but also causes so called “connection 
domain mutations” (CDMs) on RT and there is interest in N348I and its effect on second-line NNRTIs 
namely etravirine(14). The studies used to determine the frequency of this particular mutation used 
stavudine and lamivudine as their NRTI backbones with efavirenz being compared to nevirapine(14). The 
frequency of the CDMs was higher in the nevaripine cohort – 45% compared to the efavirenz cohort – 
12%(39). Its effect on etravirine however seems to depend on the presence of added mutations as the 
presence of N348I in isolation does not reduce etravirine activity significantly(14).  
 
Determining which variables are associated with the development of resistance has been a focus of many 
studies. Age, gender, employment, recent opportunistic infection, CD4 count at the time of enrollment, 
plasma HIV viral load at the time of enrollment and WHO stage are  some of the variables that have been 
considered(40). Marconi et al found that patients with viral loads of between 5000 – 99,999 copies/ml at 
initial recruitment were more likely to develop mutations. This is in contrast to Wallis et al who found that 
the pre-treatment viral load did not have  a significant relationship with virological failure and that subjects 
who failed were more likely to have low CD4 cell counts(15). The other variables listed above did not seem 
to be associated with treatment failure in a statistically significant way in that study. Another variable that 
may be considered to influence the development of resistance is the prior use of suboptimal antiretroviral 
therapy. One would expect that when single or dual–therapy regimens are used that this would generate 
mutations to those drugs due to the limited viral suppression provided by the chosen agents, therefore having 
an impact on subsequent regimens, but not all studies have confirmed this (40). 
 
Optimal drug adherence ensures viral load suppression and helps ensure clinical response to ART. The exact 
level of adherence needed to prevent the development of drug resistance has been a topic of research with 
some of the earlier studies with protease inhibitors suggesting a requirement >95%(41–43). There are 
however some challenges to this research. The way in which one measures adherence can be inaccurate 
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especially in a resource limited setting where patient follow–up is already challenging. Some of the methods 
used in studies include having patients answer adherence questionnaires and working out cumulative 
adherence via formulas, pill count, prescription refill data and plasma drug concentrations(7,15,44). 
 
Not all of these methods are available in the resource-constrained public sector as most of the studies 
utilizing these above methods were conducted outside of Africa. Evidence suggests that adherence between 
70 – 90%(7) usually results in the development of resistance but there are some studies that do not reveal a 
statistically significant relationship between adherence and the development of resistance as was 
demonstrated by Marconi et al(40). This figure of 70 – 90% is probably outdated in that it applies to earlier 
ART regimens used in the 1990s and different drugs have individual adherence–resistance relationships (i.e. 
the range of adherence that is required to select out a resistance mutation). For example, Bangsberg et al 
showed that NNRTI resistance mutations develop in an adherence range of between 2 and 60% and viral 
suppression may be observed at adherence levels above 60% when NNRTI-based regimens are 
considered(11).  
 
In summary, HIV drug resistance testing may have benefit in terms of ART management decisions, but 
cannot be justified in the resource limited public health sector at first-line ART failure on account of the cost 
that this investigation incurs. There has been evidence to show that continued use of NRTI based therapy 
with a boosted PI in patients with first-line ART failure compares favorably with the use of the integrase 
inhibitor raltegravir when used in place of the NRTI backbone in achieving satisfactory viral load 
suppression(19,20). Within the private health care setting where it may be affordable it allows for a more 
targeted approach to the management of individuals experiencing first-line treatment failure. My MMed 
study describes the resistance mutation patterns observed in the private sector in South Africa after first-line 
ART failure and gives us an opportunity to compare our results with studies done in the public sector. There 
may be important differences observed that require further exploration. The development of resistance to 
ART agents is a topic that cannot be ignored and will ultimately become a public health problem resulting in 
an increase in the burden on an already strained health care system. The limited choice of ART agents 
available for use in the public health care system in sub-Saharan Africa provides a compelling reason to 
ensure that best practice is at the forefront in terms of adherence counseling and drug choices and supply 
thereby allowing us to preserve more costly second- and third-line ART agents. 
 
As is evident from this review, studies characterizing drug resistance mutations detected when individuals 
experience first-line failure in sub-Saharan Africa have mainly been conducted in the public sector. Few, if 
any, studies have been done focused on drug resistance patterns in the private sector where genotyping is 
more frequently done in clinical practice and data regarding patient characteristics, comorbidities and 
relevant drug history is accessible. The study that I conducted for my MMed of drug resistance in a private 
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Background: First-line antiretroviral therapy (ART) regimen choices have evolved over the 
past 15 years in South Africa. Many patients develop HIV drug resistance mutations when 
they fail first-line ART. The effect of different drug regimens and other patient related factors 
on drug resistant mutations selected at first line failure are not well characterised in Southern 
Africa with its predominantly subtype C epidemic. 
 
Objectives: To characterize HIV resistance mutations in patients failing first-line ART in the 
private sector in Southern Africa, and risk factors associated with resistance and particular 
resistance mutations. 
 
Methods: This was a retrospective observational study linking two databases. One database 
was that of the Aid for AIDS (AfA) disease management programme (for clinical and ART 
regimen data) and the other was that of Lancet Laboratories where HIV genotypic sequence 
data were stored. Variables included in analyses were age, gender, province, WHO stage at 
time of resistance testing (HIVDR), duration of ART at HIVDR, prior monotherapy or dual 
therapy, viral load and CD4 count prior to starting ART, viral load and CD4 count at HIVDR, 
duration that the viral load was >400 copies/ml prior to HIVDR and HIV subtype. Data on 
patients who had a resistance test between 2008 and 2014 while failing first line ART was 
extracted from these databases. Fisher’s exact test and Chi-squared test were used to analyse 
categorical variables and Wilcoxon rank sum test for continuous variables. For multivariate 
analyses, logistic regression models were used. 
 
Results: Patients who registered with AfA between 1998 and 2013 and had a resistance test 
performed whilst experiencing viral failure on a non-nucleoside reverse transcriptase 
inhibitor (NNRTI) regimen with no history of prior failure on a protease inhibitor (PI) 
regimen were included: 265 (95.3%) patients had a reverse transcriptase mutation of any 
kind, 253 (91%) had an NNRTI mutation and 246 (88.5%) had a nucleoside reverse 
transcriptase inhibitor (NRTI) mutation (n=278). The commonest mutation was the M184V 
mutation (80.6%), 44.2% had at least one thymidine analogue mutation (TAM) and 42.1% 
had the K103N/S mutation. Notably there was a median of 18 months during which the viral 
load was not suppressed prior to the resistance tests, which likely contributed to the high 
prevalence of mutations. A total of 83 (29.9%) patients were found to have the K65R 
mutation, 72 of these patients were on tenofovir (TDF) at the time of resistance testing 
demonstrating the strong association between TDF and the K65R mutation.  
 
Conclusions: The mutational patterns observed in our study and their prevalence were 
similar to those noted in previous studies done within the region’s public sector. There was a 
high prevalence of the K65R mutation in patients failing TDF-containing regimens. A longer 









Antiretroviral therapy (ART) first became available in the South African private sector in the 
late 1990s and in the public sector in 2004. An increasing number of individuals have been 
started on ART such that South Africa now has the highest number of people on ART in the 
world: an estimated 3 million in the public sector have started ART and several hundred 
thousand in the private sector (45). As a result, the emergence of ART resistance has become 
one of the major concerns. Amongst the challenges that face South Africa, with its resource 
limitations in terms of health care provision, is finding cost effective ways to prevent ART 
resistance and if it occurs to detect it early and change treatment appropriately. 
 
In South Africa, virological failure on ART is defined as an HIV viral load of >1000 
copies/ml on at least two separate occasions more than 24 weeks after ART initiation or a 
drop in viral load <log 1.5 from baseline at 12 weeks post initiation (15). The development of 
resistance results in an inability of the drugs to inhibit the replication of the human 
immunodeficiency virus (HIV) and it then becomes necessary to change to a new ART 
regimen without significant cross-resistance in order to avoid both immunological and 
clinical decline. 
 
Resistance mutations are usually a result of a single nucleotide substitutions in a particular 
region of the gene encoding an HIV protein.  These amino acid changes result in a structural 
or charge change to the protein which interferes with ART drug binding or action. The 
commonest HIV resistance mutations described include the M184V mutation associated with 
lamivudine, K103N as well as Y181C mutations associated with NNRTI failure and the 
thymidine analogue mutations (TAMs) selected for by zidovudine (AZT) and stavudine 
(D4T) namely: M41L, D67N, L210W, K70R,T215Y/F, and K219Q/E. Of concern is the 
emergence of complex mutational patterns which allow for resistance across a broad 
spectrum of drugs within a class and may have implications for the choice of drugs in 
second-line therapy. These include the K65R, Q151M, T69 insertion and the presence of 
more than three TAMs (46). 
 
Adherence in the range between 70-90% has been shown to contribute to the development of 
resistance. Excellent adherence has been shown to be the most important preventer of 
resistance development (12,47). There is an opportunity to describe connections between 
ART drugs used in first-line regimens and the resultant mutational patterns when the regimen 
fails in the private sector in Southern Africa because access to resources for genotypic 
resistance testing has allowed for this testing. Analyzing this data will potentially broaden our 
understanding of the mutational patterns occurring in ART programmes within subtype C 
epidemics and inform on the utility of NRTI drugs and NNRTI drugs in subsequent lines of 
therapy. Second-generation NNRTI drugs (rilpivirine and etravirine) may be considered in 
third line ART regimens when there is extensive resistance to other ART classes.  
 
Our primary aim was to characterize the frequency and the patterns of genotypic resistance in 
the private sector in South Africa among individuals experiencing first-line ART failure. 
Secondary objectives included determining clinical and treatment factors associated with 
resistance and particular mutations. A specific focus was to evaluate which baseline and on 








Our study included individuals who started ART between 1998 and 2013, and had a 
genotypic resistance test done between 2008 to 2014. It was a retrospective observational 
study linking two database sources. The one source was from the Aid for AIDS (AfA) 
disease management programme which included clinical and demographic data from 
individuals who received ART in the private sector within their programme. The second 
database was that of the Lancet Laboratories where samples from certain individuals 
registered with AfA were sent for resistance testing when the individuals were found to be 
failing an ART regimen. These two databases were linked to address the study aims. The 
study included all AfA registered individuals failing a first-line NNRTI-based ART regimen 
who had a resistance test performed by Lancet Laboratories. Adult and paediatric patients 
were included. 
 
The following information was extracted from the AfA clinical database: age, gender, 
province of residence, baseline CD4 count and CD4 count at resistance test, baseline viral 
load and viral load at resistance test, duration on ART at resistance test, first line drugs 
individuals had been exposed to including changes made as well as the duration taking drugs, 
the duration of documented unsuppressed viral loads (viral load > 400 copies/ml) prior to 
resistance testing, and baseline World Health Organization (WHO) stage. The viral subtype 
and resistance-associated NRTI and NNRTI resistance mutations were accessed from the 
Lancet Laboratory database. The 2014 IAS-USA HIV drug resistance list was used to define 
significant resistance mutations associated with NRTIs, nevirapine (NVP) and efavirenz 
(EFV) that were then recorded for these analyses. All data was de-identified after linking and 
analyses were performed on the de-identified data.  
 
Aid for AIDS (AfA)Disease Management Programme 
AfA was launched in May 1998 and is a private sector HIV disease management programme 
that provides clinical interventions coupled with clinical and patient support and on-going 
adherence management for patients on medical aid schemes and corporate treatment 
programmes in Southern African. The aim of the programme is to partner with healthcare 
providers and healthcare funders to optimize clinical outcomes by ensuring access to 
effective ART and regular monitoring of outcomes and potential toxicity, thus limiting the 
frequency of treatment failure due to poor adherence or adverse effects. Over 78,000 patients 
are currently registered (more than 272,000 patients have been registered cumulatively to 
date). 
  
The AfA Clinical Guidelines are regularly revised and updated by the expert consultants on 
the AfA Clinical Advisory Committee in the light of new developments in HIV management, 
as a result of the availability of new drugs and tests and changes in starting criteria. Doctors 
are required to prescribe treatment in line with the AfA guidelines but may motivate for an 
individualized approach where indicated. 
   
Patients need to be registered on the Aid for AIDS (AfA) programme to have ART 
medication and blood results paid from their HIV benefit. The treating doctor can complete 
an application form or call to telephonically register their patient. During registration the 
doctor will provide relevant blood results, clinical staging information and previous treatment 
history, where applicable. This data is saved on the AfA database. Once registered, AfA 
authorize an appropriate ART regimen in discussion with the patient’s doctor and assign 
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relevant monitoring follow-ups for pathology testing. 
  
Monitoring results (for example CD4 count and HIV viral load) may be received from the 
doctor, submitted electronically to AfA via a file transfer process or AfA may contact the 
laboratory directly to receive the results. All changes to drug regimens are recorded as well as 
the reason for the change. A comprehensive note is made with each intervention on the file. 
All data is loaded on the AfA electronic database. 
 
Although the AfA operates in the private sector, its guidelines are similar to the WHO 
guidelines with a standardized approach to first-line (NNRTI-based) and second-line 
(protease inhibitor-based) ART regimens. Important differences between AfA and the public 
sector ART programme in South Africa are: (i) the AfA programme started in 1998 whereas 
the public sector programme started in 2004; (ii) in AfA some patients received initial ART 
with monotherapy or dual NRTIs for affordability reasons in the late 1990s; (iii) certain drugs 
were available in the private sector before the public sector; and (iv) resistance testing has 
been available for patients failing ART in AfA since 2001. 
 
Resistance testing at Lancet laboratories 
HIV drug resistance testing is performed at Lancet Laboratories using a laboratory developed 
assay.  Briefly, viral RNA is extracted from plasma and amplified to include the full protease 
and partial reverse transcriptase regions.  These regions are sequenced using population based 
sequencing platform.  HIV drug resistance mutations are detected using the Stanford database 
(https://hivdb.stanford.edu) and the subtype defined using the Rega HIV subtyping tool 
(http://www.bioafrica.net/rega-genotype/html/subtypinghiv.html).   
 
Statistical analyses 
For univariate analysis of categorical variable Fisher’s exact test and Chi squared tests were 
used and Wilcoxon rank sum test was used for continuous variables.  Spearman rank-order 
correlation coefficient was used to analyse the strength and direction of associations between 
ordinal and continuous variables.  As presence of mutations were very common, log-binomial 
regression analysis was performed using Stata 13 (StataCorp, College Station, TX), with all 
variables hypothesised to be associated with outcome included in the models. Log 
transformation was applied to variables with highly skewed distributions.  Risk ratios (RR) 
were presented together with 95% confidence intervals (CI).  Adjusted RRs were not 
estimated in multivariable models that failed to converge. A p-value < 0.05 was regarded as 
significant. 
 
Ethical approval and consent 
This was obtained from the UCT Human Research Ethics Committee (HREC REF 380/2014 
and 112/2013). Upon entering the AfA programme patients sign consent to have their data 
analyzed for programme evaluation and research. The wording on the registration form that 
the patients sign is: “I herewith authorize AfA and its agents/medical staff to disclose the 
medical information relevant to my HIV infection to third parties for the purpose of scientific, 
epidemiological and/or financial analysis without disclosure of my identity.” The UCT 
HREC specifically provided permission for this retrospective observational study to be 
performed linking the AfA and Lancet Laboratories databases provided that the patient data 







The study included 278 individuals registered with AfA who had a resistance test performed 
at Lancet laboratories at the time they were failing an NNRTI regimen, without prior 
exposure to a PI regimen. These individuals started ART between 1998 and 2013. The 
resistance tests were performed between 2008 and 2014.  
 
The median age was 37 years (interquartile range (IQR) = 28-43) (Table 1). The majority 
were over the age of 18 years (n=225; 80.9%). Of the 278 patients, 172 were female (61.9%). 
The majority of individuals resided in KwaZulu Natal (43.0%) and Gauteng Province 
(28.5%). World Health Organization (WHO) stage at ART initiation was available for 131 
patients: two-thirds were stage 3 or 4. Of the 226 patients for whom this information was 
available, 9 (4%) had been historically exposed to ART monotherapy and 27 (12%) had been 
historically exposed to ART dual therapy. Patients had been on ART for a median of 29 
months (IQR=15-53) at the time of resistance test. The common NRTIs that patients were 
receiving were TDF (50.0%), emtricitabine (FTC) (49.6%), lamivudine (3TC) (44.2%), and 
AZT (31.7%). For the NNRTIs, 81.7% of patients were receiving EFV and 18.4% were 
receiving NVP. In terms of historical exposure to NRTIs, 63.3% patients had ever received 
3TC, 54.9% TDF, 54.9% FTC, 46.0% AZT, 23.9% D4T, 10.2% didanosine (DDI) and 8.9% 
abacavir (ABC).  
 
The HIV viral load prior to ART was a median of 235,000 copies/ml and CD4 count prior to 
ART was a median of 78 cells/mm3 (data for these two data points was missing for 47 
patients). At the time of resistance testing median HIV viral load 85,688 copies/ml (data 
missing for 15) and median CD4 count was 115 cells/mm3 (data missing for 14). The HIV 
viral load had been documented to be unsuppressed (greater than 400 copies/ml) for a median 
of 18 months (IQR = 11-34) at the time of resistance testing. HIV subtype C was the 
predominant subtype (98.6%). 
 
Frequency of resistance mutations 
Of the 278 patients, 265 (95.3%) had any reverse transcriptase resistance mutation (Table 2):  
246 (88.5%) patients had at least one NRTI mutation and 253 (91%) had at least one NNRTI 
mutation. At least one thymidine analogues mutation (TAM) was present for 123 (44.2%) of 
the patients and the K65R mutation was present for 83 (29.9%) patients. Frequency of 
individual mutations is shown in Figure 1 and 2. The number of NNRTI mutations and 
TAMs are shown in Figures 3 and 4 respectively.  
 
Influence of drug exposure to TDF on mutations detected 
A total of 150 (54%) patients ever exposed to TDF were compared with 128 (46%) never 
unexposed to TDF and evaluated for the presence of associated mutations in each group 
(Table 3). NRTI mutations were found in 134 vs. 112 patients and there was no statistically 
significant difference (89.3% vs. 87.5% p=0.633). For the NRTI associated mutations the 
M184V/I mutation was the most prevalent, 128 vs. 96 patients (85.3% vs. 75.0%, p=0.03). 
As expected the K65R mutation was more common in those who had exposure to TDF, 
present in 72 vs. 11 patients (48% vs. 8.6%, p < 0.001). The K70E mutation (another 
mutation known to be associated with TDF) occurred in 27 vs. 1 patient (18% vs. 0.78%, p < 
0.001). TAMs occurred less frequently in the TDF exposed group 49 vs. 74 patients (32.7% 
vs. 57.8% p < 0.001). The commonest TAM occurring in the TDF exposed group being 
D67N, 28 vs. 38 (18.7 vs. 29.7, p=0.031). The T215Y/F was the commonest TAM found in 
the TDF unexposed group, 10 vs. 47 (6.7% vs. 36.7%, p < 0.001). 
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It was found that 137 vs. 116 patients (91.3% vs. 90.6%, p=0.837) had NNRTI mutations.  
There was a statistically significant different difference between groups for 2 mutations: the 
V106A/M mutation was more common in the group exposed (n=65; 43.3%) to TDF 
compared to those that had had no TDF exposure (n=40; 31.3%;  p=0.038). Similarly, the 
L100I mutation, although rare, was more common in those exposed to TDF (10.7% vs. 3.1%, 
p=0.019).   
 
NRTI drugs at resistance test and common mutations  
The most frequently used first NRTI by patients at the time of resistance testing was TDF 
followed by AZT and D4T (n=139 (50%), n=88 (31.7%) and n=26 (9.4%) respectively) 
(Table 4). The M184V mutation was the commonest NRTI mutation across the all categories 
(p=0.037); occurring in 119 (85.6%), 66 (75%), 17 (65.4%) and 22 (88%) of TDF, AZT, D4T 
and other drug exposed groups respectively. The K65R mutation showed a predilection for 
occurring with TDF exposure at time of resistance test occurring in 72 (52%) of the TDF 
exposed patients. It was far less common in the other groups occurring in 5 (5.7%), 2 (7.7%) 
and 4 (16%) of the patients exposed to AZT, D4T and other ART drugs respectively. TAMs 
occurred frequently in the AZT exposure group 57 (64.8%) and were also noted in 16 
(61.5%), 44 (31.7%) and 6 (24%) patients exposed to D4T, TDF and other ART drugs 
respectively.  For the majority of patients, the second drug at resistance test was 3TC or FTC; 
these were not included in this analysis. 
 
Risk factors for TAMs 
Risk factors for TAMs were analysed using univariate analysis (Supplementary table 1). The 
multivariate model could not be run due to non-convergence. Variables that were found to be 
significantly associated with presence of one or more TAM on the resistance test included 
duration on ART (RR=2.32, 95%CI 1.69 – 3.17, p < 0.001), duration failing ART (RR=1.60, 
95%CI 1.18 – 2.16, p=0.002), being on DDI at resistance test (RR=1.70, 95%CI 1.33 – 2.16, 
p <0.001) and any exposure to DDI (RR=2.05, 95%CI 1.63 – 2.58, p<0.001), AZT 
(RR=1.89, 95%CI 1.44 – 2.5, p<0.001), D4T (RR=1.46, 95%CI 1.13 – 1.90, p=0.004) as well 
as 3TC (RR=1.42, 95%CI 1.05 – 1.93, p=0.023).  
 
Risk factors for K65R mutation 
In the univariate analysis of risk factors for the presence of the K65R mutation 
(Supplementary table 2) unsurprisingly TDF was the most significant factor (RR=9.12, 
95%CI 3.83 – 21.68, p<0.001). The presence of FTC in the drug regimen was also associated 
(RR=5.75, 95%CI 3.20 – 10.34, p<0.001). Being older than 18 years of age was also a risk 
factor (RR=3.70, 95%CI 1.24 – 1.02, p=0.019). On multivariate analysis the presence of TDF 
(RR=30.54, 95%CI 8.15 – 114.5, p<0.001) and NVP (RR=1.59, 95%CI 1.17 – 2.17, 
p=0.003) in the regimen were significantly associated with the presence of the K65R 
mutation. Interestingly, the presence of FTC in the regimen appeared protective after 
adjustment. 
 
Risk factors for NNRTI resistance mutations 
In univariate analysis only ever being exposed to NVP (RR=1.08, 95%CI 1.01 – 1.15, 
p=0.027) was found to be significantly associated with NNRTI mutations (Supplementary 
table 3). The multivariate model could not be run due to non-convergence. 
 
Frequency of mutations in relation to duration on ART and failing ART 
There was a statistically significant correlation between duration on ART and number of 
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TAMs (Supplementary figure 1) and between duration failing ART and number of TAMs 
(Supplementary figure 2), although in both instances the strength of the correlation was weak 
(r=0.293 and r=0.231 respectively). There was no significant correlation between duration on 
ART or duration failing ART and number of NNRTI mutations on the resistance test 





Of the patients included in this study, 95.3% were found to have at least one resistance 
mutation and of these 88.5% were found to have one or more NRTI mutation and 91% were 
found to have one or more NNRTI mutation. Of importance 44.2% of the patients were found 
to have TAMs and 29.9% had the K65R mutation. These results were noted to be consistent 
with studies done in the public sectors of sub-Saharan Africa (15,17,40). In our study the 
M184V (80.6%) and the K103N/S (42.1%) mutations occurred prominently.  
 
The frequency with which K65R was present was strongly related to the drug regimen the 
patient was on at the time of resistance testing – occurring mainly with TDF. Tang et al 
analysed 35 studies from various countries around the world of which 65% were from sub-
Saharan Africa; they found the K65R mutation in 6.2% of patients on a D4T based regimen 
contrasted with Sunpath et al, whose study population from KwaZulu Natal, found the same 
mutation in 69.7% of the cohort who were initiated on a TDF containing regimen(28,33).This 
association was further described most recently by Rhee et al confirming the importance of 
the link between these two variables(52). We found that 51.8% of the patients on a TDF 
containing regimen at resistance test had the K65R mutation compared with 5.7% of patients 
on AZT and 7.7% of patients on D4T, confirming the expected association between TDF and 
K65R. In addition, 19.4% of the patients on TDF at resistance test also had the K70E 
mutation which has been shown to confer resistance to TDF. It was strongly associated with 
TDF exposure in our cohort. Aside from TDF being the most important risk factor for the 
K65R mutation, FTC being the second NRTI in the regimen was also associated with 
increased risk of having the K65R mutation in univariate analysis, but was protective in 
multivariate analysis. The univariate finding is likely explained by FTC only being available 
in a fixed dose combination with TDF in SA, thus always being accompanied by TDF in a 
regimen. Being on NVP at resistance test was not a significant risk factor in univariate 
analysis but was significantly associated with K65R in multivariate analysis. This may be 
related to NVP providing a less potent ART regimen than EFV(48).  
 
TAMs were most commonly found in patients on an AZT containing regimens at resistance 
test (61.5%) and occurred less commonly in those on TDF based regimens (35.6%). The 
presence of the K65R mutation may have played a role in the decreased frequency of TAMs 
in those on TDF based regimens as these mutations are considered to be mutually exclusive 
in their occurrence(16,28). In univariate analysis duration on ART prior to resistance testing 
and duration documented to be failing ART were found to be significant factors associated 
with the presence of TAMs. Similar to our findings, Orrell et al reported that patients in their 
cohort tested for resistance beyond 6 months had a greater accumulation of TAMs, denoting 
the important association between duration on failing regimens and the prevalence of TAMs, 
with similar findings in other studies (17,29,40,49,50,55,56). Prior exposure to DDI, D4T and 
3TC were also found to be important predisposing factors for TAMs. Ever being exposed to 
NVP was associated with presence of at least one NNRTI mutation. This is potentially 
important when considering the choice of NNRTI in first line (51). 
 
Our study was conducted within the Southern African private sector and using data collected 
between 1998 and 2014. In 2010 the National Department of Health began to phase out the 
use of D4T due to its side effect profile and replaced it with TDF; this shift occurred slightly 
earlier in the private sector. As such over half the cohort time predated the introduction of 
TDF in first line. This had a role to play on the proportion of patients who developed some of 
the resistance mutations in question such as the K65R mutation. In our cohort, 51.8% of 
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patients failing tenofovir (TDF) regimens showed K65R (similar to the study by Sunpath et 
al (69.7%)) but K65R was observed in less than 10% of patients failing stavudine or 
zidovudine. We also found that the presence of TDF and NVP in a regimen was associated 
with the presence of the K65R mutation and this is consistent with various studies previously 
done(32,53). This has contributed to the preferred use of TDF/FTC/EFV as first line therapy 
as this combination has been shown to result in fewer cases of treatment failure (32,53). 
 
Resistance testing was done in patients that were failing ART, which was defined as a viral 
load of > 1000 copies/ml on two consecutive occasions 24 weeks after ART commencement 
(15). In our cohort the viral load was unsuppressed for a median of 18 months. This means 
there was a prolonged period of exposure to a failing regimen allowing for the selection of 
TAMs and contributing to the high proportion of patients who had TAMs and who had 
resistance mutations in general on resistance testing. The long duration that patients were 
failing ART before resistance testing represents a bias in the selection of patients for 
resistance testing within the AfA programme. Particularly during the earlier years of 
resistance testing because of the cost these tests were generally restricted to patients with 
prolonged failure as it was anticipated they would have complex NRTI resistance patterns 
and thus the test would help in decisions regarding drugs to be included in second-line 
regimens. The findings are therefore not representative of all patients failing first-line ART in 
the private sector. A further limitation of the study was that data for certain variables was 
missing for a proportion of patients, especially baseline variables those who started ART 
before registered with AfA (see Table 1 footnote). 
 
It is worth noting that the association noted between the V106M/A mutation and TDF is 
likely confounded due to the frequent co-administration of EFV with TDF, as they are co-




The key findings of this study are characterisation of the mutational patterns at first-line 
failure in the private sector in South Africa. There was a strong association between TDF and 
K65R; this mutation was seen in over 50% of the patients on TDF at first-line failure. K65R 
confers resistance to most NRTI’s with the exception of AZT where it conversely increases 
susceptibility(6,28). This limits the NRTI choices available for second-line therapy, although 
recent clinical trials have questioned whether susceptible NRTI drugs are necessary for the 
virological efficacy of a lopinavir/ritonavir-based second-line regimen (19,20). There were 
few patients noted to have the Q151M mutation which may be associated with K65R (n=2) 
and when together result in pan-nucleoside resistance (6,28). Patients on  TDF at resistance 
test were found to have the Y181C/I mutation more frequently than in AZT and D4T,  
(26.6% vs. 11.4% vs. 19.23% respectively) which has implications for susceptibility to the 
second generation NNRTI etravirine(46). As noted above these patients were virologically 
unsuppressed for a median of 18 months at time of resistance testing and duration 
unsuppressed was a risk factor for the development of TAMs. TAMs confer resistance to 
D4T and AZT and if patients are found to have more than 3 TAMs it causes resistance to 
most NRTI’s available for second-line therapy. 
 
We have shown that prolonged exposure to a failing first-line regimen is associated with very 
high proportion of patients having complex resistance mutation patterns. The roll-out of TDF 
appears to have substantially increased the proportion of patients with K65R at first-line 
failure, affecting the choices for future NRTIs in subsequent lines of therapy. Interestingly 
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TDF was associated with NNRTI mutations that have implications for etravirine in third-line 
therapy. Our findings paralleled the findings of studies done in the SA public sector regarding 
K65R. The use of resistance testing to identify mutational patterns at failure may be of 
benefit in facilitating subsequent regimen choices, but this has to be balanced against the cost 
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Table 1: Characteristics of patients  
 
Variable  Number (%) or median (interquartile 
range) 
Age in years, median (IQR)  
< 10 years, n (%) 
10 – 17 years, n (%) 
>=18 years, n (%) 




Gender, n (% female)  172/278 (61.87) 
Province*, n (%)   
Eastern Cape 10/256 (3.91) 
Free State 1/256 (0.39) 
Gauteng 73/256 (28.52) 
KwaZulu/Natal 110/256 (42.97) 
Limpopo 25/256 (9.77) 
Mpumalanga 23/256 (8.98) 
North-West 13/256 (5.08) 
Northern Cape 0/256 (0%) 
Western Cape 1/256 (0.39) 
WHO stage*, n (%)   
Stage 1 26/131 (19.85) 
Stage 2 20/131 (15.27) 
Stage 3 55/131 (41.98) 
Stage 4 30/131 (22.90) 
Duration of ART in months, median (IQR) 29 (15 - 53) 
Monotherapy*, n (% yes)   9/226 (3.98) 
Dual therapy*, n (% yes)  27/226 (11.95) 
Drug at RT, n (% yes)   
AZT 88/278 (31.65) 
D4T 26/278 (9.35) 
TDF 139/278 (50.00) 
ABC 23/278 (8.27) 
DDI 2/278 (0.72) 
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3TC 123/278 (44.24) 
FTC 138/278 (49.64) 
DDI 17/278 (6.12) 
EFV 227/278 (81.65) 
NVP 51/278 (18.35) 
Drug, ever on*, n (% yes)   
AZT 104/226 (46.02) 
D4T 54/226 (23.89) 
TDF 124/226 (54.87) 
ABC 20/226 (8.85) 
DDI 23/226 (10.18) 
3TC 143/226 (63.27) 
FTC 124/226 (54.87) 
EFV 196/226 (86.73) 
NVP 65/226 (28.76) 
HIV viral load in copies/ml before ART, median 
(IQR)  
235,000 (82,924 – 562,000) 
CD4 count in cells/mm3 before ART, median 
(IQR)  
78 (27 - 178) 
HIV viral load before RT, median (IQR)  85,688 (22,683 – 244,506) 
CD4 count before RT, median (IQR)  115 (33.50 - 293.50) 
Duration viral load > 400 copies/ml prior to 
resistance test, 
 
18 (11 - 34) 
Subtype   
C, n (%) 274/278 (98.56) 
B, n (%) 1/278 (0.36) 
C/B, n (%) 1/278 (0.36) 
Other, n (%) 2/278 (72) 
* n varies due to missing values 
 
Footnote: 52 patients who were not registered with AfA when they initiated ART baseline data at the start of 
ART and data related to their early ART history was consistently missing – these patients transferred into AfA 
while already on ART. These 52 patients were not included in analysis of CD4 count and viral load before ART, 
WHO stage, previous mono/dual therapy, drugs ever on, duration on ART and duration failing ART (unless data 
could be accessed from narrative notes at time of entry into AfA which was available for a small number of 




Table 2: Mutations present on resistance test 
 
Mutations (n = 278) 
Any RT mutation  




4 (3 – 5) 
TAMS  




2 (1 – 3) 
NRTI 




2 (1 – 3) 
NNRTIs 




2 (1 – 2) 
K65R 








Table 3: Mutations associated with tenofovir (TDF) exposure 
 
Mutations Exposed to TDF 
(n=150; %) 
Unexposed to TDF 
(n=128; %) 
p-value 
NRTIs    
T69INS           - - - 
Q151M 2 (1.33) 3 (2.34) 0.664 
M41L 8 (5.33) 36 (28.12) <0.001 
D67N 28 (18.67) 38 (29.69) 0.031 
K70R 11 (7.33) 33 (25.78) <0.001 
L210W 0 (0.00) 5 (3.91) 0.020 
T215Y/F 10 (6.67) 47 (36.72) <0.001 
K219Q/E 24 (16.00) 31 (24.22) 0.086 
K65R 72 (48.00) 11 (8.59) <0.001 
K70E 27 (18.00) 1 (0.78) <0.001 
L74V 6 (4.00) 15 (11.72) 0.015 
Y115F 18 (12.00) 10 (7.81) 0.248 
M184V/I 128 (85.33) 96 (75.00) 0.030 
NRTIs, n (% yes) 134 (89.33) 112 (87.50) 0.633 
Total number NRTI 
mutations,  
median (IQR) 
2(1 - 3) 2.5 (1 - 4) 0.152 
TAMS    
TAMs, n (% yes) 49 (32.67) 74 (57.81) <0.001 
Total TAMS,  
median (IQR) 
2 (1 – 3) 3 (1 - 4) 0.110 
NNRTIs    
L100I            16 (10.67) 4 (3.12) 0.019 
K101P 3 (2.20) 3 (2.34) 1.000 
K103N/S 61 (40.67) 56 (43.75) 0.604 
V106A/M 65 (43.33) 40 (31.25) 0.038 
V108I 15 (10.00) 11 (8.59) 0.688 
Y181C/I 37 (24.67) 20 (15.62) 0.063 
Y188C/L/H 18 (12.00) 20 (15.62) 0.381 
G190S/A 48 (32.00) 34 (26.56) 0.322 
P225H 13 (8.67) 15 (11.72) 0.399 
M230L 6 (4.00) 4 (3.12) 0.757 
NNRTIS, N (%) 137 (91.33) 116 (90.62) 0.837 
Total number NNRTI 
mutations,  
median (IQR) 
2 (1 – 2) 2 (2 – 2) 0.007 
* n varies due to missing values  
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NRTIs, n¥ (%)      
T69INS           - - - -  
Q151M 2 (1.44) 0 (0.00) 3 (11.54) 0 (0.00) 0.009 
M41L 6 (4.32) 29 (33.95) 7 (26.92) 2 (8.00) <0.001 
D67N 25 (17.99) 32 (36.36) 6 (23.01) 3 (12.00) 0.008 
K70R 9 (6.47) 27 (30.68) 5 (19.23) 3 (12.00) <0.001 
L210W 0 (0.00) 4 (4.55) 1 (3.85) 0 (0.00) 0.035 
T215Y/F 7 (5.04) 40 (45.45) 7 (26.92) 3 (12.00) <0.001 
K219Q/E 21 (15.11) 25 (28.41) 5 (19.23) 4 (16.00) 0.108 
K65R 72 (51.80) 5 (5.68) 2 (7.69) 4 (16.00) <0.001 
K70E 27 (19.42) 1 (1.14) 0 (0.00) 0 (0.00) <0.001 
L74V 2 (1.44) 1 (1.14) 1 (3.85) 17 (68.00) <0.001 
Y115F 15 (10.79) 1 (1.14) 1 (3.85) 11 (44.00) <0.001 
M184V/I 119 (85.61) 66 (75.00) 17 (65.38) 22 (88.00) 0.037 
NRTIs, n (%yes) 125 (89.93) 75 (85.23) 23 (88.46) 23 (92.00) 0.728 
TOTAL NRTIS, 
median (IQR) 
2 (1 – 3) 3 (1 – 4) 2 (1 – 3) 3 (2 – 3) 0.128 
      
TAMS, n (%yes) 44 (31.65) 57 (64.77) 16 (61.54) 6 (24.00) <0.001 
Total TAMS 
median (IQR) 
2 (1 – 3) 3 (1 – 4) 2 (1 – 3) 3 (2 – 4) 0.067 
      
NNRTIS, n (%)      
L100I            16 (11.51) 2 (2.27) 1 (3.85) 1 (4.00) 0.046 
K101P 3 (2.16) 2 (2.27) 1 (3.85) 0 (0.00) 0.827 
K103N/S 56 (4. 29) 42 (47.73) 11 (42.31) 8 (32.00) 0.498 
V106A/M 62 (44.60) 24 (27.27) 11 (42.31) 8 (32.00) 0.058 
V108I 13 (9.35) 8 (9.09) 3 (11.54) 2 (8.00) 0.972 
Y181C/I 37 (26.62) 10 (11.36) 5 (19.23) 5 (20.00) 0.052 
Y188C/L/H 14 (10.07) 12 (13.64) 7 (26.92) 5 (20.00) 0.100 
G190S/A 45 (32.37) 25 (28.41) 6 (23.08) 6 (24.00) 0.686 
P225H 12 (8.63) 13 (14.77) 2 (7.69) 1 (4.00) 0.394 
M230L 6 (4.32)  2 (2.27) 1 (3.85) 1 (4.00) 0.768 
NNRTIs, n (%yes) 127 (91.37) 81 (92.05) 24 (92.31) 21 (84.00) 0.625 
Number of NNRTI 
mutations median 
(IQR) 
2 (2 – 2) 2 (1 – 2) 2 (2 – 2) 2 (1 – 2) 0.010 
¥n varies due to missing values 
 
Footnote: This table summarises data according to the first NRTI drug in the ART regimen 
at resistance test. For the majority of patients, the second drug at resistance test was 3TC or 
FTC, and these were not included in this analysis.   
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Supplementary table 1: Unadjusted risk ratios for variables associated with TAMs 
 
 Univariate 
Variable  RR (95%CI) P value 
Age group*   
10 -18 years 1.02 (0.63 – 1.64) 0.949 
>18 years 0.73 (0.52 – 1.04) 0.078 
Gender** 0.87 (0.66 – 1.13) 0.303 
Duration ART (log) 2.32 (1.69 – 3.17) <0.001 
Duration failing (log) 
Duration VL>400 
1.60 (1.18 – 2.16) 0.002 
Drug 1 at RT† (ref: AZT) 
D4T 0.95 (0.68 – 1.34) 0.768 
Other 0.37 (0.18 – 0.76) 0.006 
TDF 0.49 (0.370 – 0.65) <0.001 
Drug 2 at RT†† (ref: 3TC)   
FTC 0.61 (0.46 – 0.82) 0.001 
DDI 1.70 (1.33 – 2.16) <0.001 
Drug 3 at RT¶ (ref: EFV)   
NVP 1.19 (0.88 – 1.62) 0.262 
Drug, ever on§ 
AZT 1.89 (1.44 – 2.5) <0.001 
D4T 1.46 (1.13 – 1.90) 0.004 
TDF 0.57 (0.43 – 0.74) <0.001 
ABC 0.36 (0.14 – 0.88) 0.025 
DDI 2.05 (1.63 – 2.58) <0.001 
3TC 1.42 (1.05 – 1.93) 0.023 
FTC 0.57 (0.44 – 0.75) <0.001 
EFV 0.79 (0.57 – 1.10) 0.162 
NVP 1.14 (0.86 – 1.51) 0.349 
*  Reference group 4 -10 years 
**  Reference group male 
†  Reference group AZT 
††  Reference group 3TC 
¶  Reference group EFV 
§ Reference group ‘never on’   
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Supplementary table 2: Unadjusted and adjusted risk ratios for variables associated 
with K65R  
 
 Univariate Multivariable 
Variable  RR (95%CI) P value RR (95%CI) P value 
Age group*     
10-18 years 1.02 (0.19 - 5.57) 0.986 1.31 (0.25- 6.92)  
 
0.752 
>18 years 3.70 (1.24 - 1.02) 0.019 0.80 (0.18-3.54) 0.771 
Gender** 1.43 (0.96 - 2.14) 0.081 0.98 (0.69-1.39)  
 
0.901 
Duration ART (log) 
 




0.80 (0.54 – 1.18) 0.255 1.12 (0.79-1.57)  
 
0.532 
Drug 1 at RT †  
(ref: AZT)  
 
D4T 1.35 (0.28 - 6.58) 0.707 2.07 (0.34-12.55) 
 
0.430 
Other 2.82 (0.82 - 9.71) 0.101 4.95 (1.11-21.99) 0.036 
TDF 9.12 (3.83 - 21.68) <0.001 30.54 (8.15-114.5) <0.001 
Drug 2 at RT††  
(ref: 3TC) 
    
FTC 5.75 (3.20 - 10.34) <0.001 0.63 (0.42-0.94) 0.022 
DDI 0.66 (0.09 - 4.78) 0.679 0.81 (0.10-6.26) 0.837 
Drug 3 at RT¶  
(ref: EFV) 
    
NVP 1.06 (0.68 - 1.67) 0.792 1.59 (1.17-2.17) 0.003 
Drug, ever on§  
AZT 0.51 (0.34 - 0.76) 0.001   
D4T 0.58 (0.35 – 0.99) 0.045   
TDF 5.59 (3.10 – 10.07)  <0.001   
ABC 0.54 (0.22 – 1.34) 0.181   
DDI 0.45 (0.18 – 1.14) 0.093   
3TC 0.50 (0.35 – 0.71) <0.001   
FTC 5.12 (2.19 – 9.01) <0.001   
EFV 1.34 (0.73 – 2.45) 0.340   
NVP 1.21 (0.83 – 1.78) 0.323   
*  Reference group 4 -10 years 
** Reference group male 
†  Reference group AZT 
††  Reference group 3TC 
¶  Reference group EFV 
§ Reference group ‘never on’ 
 
Footnote: ‘A priori’ risk factors: Age, gender, duration ART, duration failing, drugs (ever, 
drug at resistance) 
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Supplementary table 3: Unadjusted risk ratios for variables associated with NNRTI 
mutations regression  
 
 Univariate 
Variable  RR (95%CI) P value 
Age group*   
10-18 years 0.10 (0.84 – 1.19) 0.986 
>18 years 1.01 (0.89 – 1.19) 0.930 
Gender** 1.06 (0.98 – 1.15) 0.162 
Duration ART (log) 1.06 (0.97 - 1.16) 0.161 
Duration failing (log) 
Duration VL > 400 
copies/ml 
1.06 (0.97 - 1.16) 0.108 
Drug1 at RT† 
(ref: AZT) 
D4T 1.00 (0.88 – 1.14) 0.965 
Other 0.91 (0.76 – 1.09) 0.324 
TD4 0.99 (0.92 – 1.08) 0.856 
Drug2 at RT†† 
(ref: 3TC) 
  
FTC 1.00 (0.93 – 1.08) 0.944 
DDI 0.97 (0.81 – 1.16) 0.735 
Drug3 at RT¶ 
(ref: EFV) 
  
NVP 1.04 (0.96 – 1.13) 0.96 
Drug, ever on§ 
AZT 1.02 (0.95 – 1.10) 0.521 
D4T 1.07 (0.99 - 1.14) 0.069 
TDF 1.01 (0.94 – 1.09) 0.837 
ABC 0.91 (0.76 – 1.09) 0.303 
DDI 1.02 (0.92 – 1.14) 0.690 
3TC 1.03 (0.95 – 1.12) 0.468 
FTC 1.01 (0.93 – 1.08) 0.867 
EFV 0.98 (0.89 – 1.09) 0.744 
NVP 1.08 (1.01-1.15) 0.027 
 
*  Reference group 4 -10 years 
** Reference group male 
†  Reference group AZT 
††  Reference group 3TC 
¶  Reference group EFV 
§ Reference group ‘never on’ 
 
 
ART abbreviations across tables: 
AZT = zidovudine; D4T = stavudine; TDF = tenofovir; ABC = abacavir; DDI = didanosine; 3TC = lamivudine; 
FTC = emtricitabine; EFV = efavirenz; NVP = nevirapine.  
 










































Figure 2: Frequency of individual non-nucleoside reverse transcriptase inhibitor 

























































Figure 4: Frequency of non-nucleoside reverse transcriptase inhibitor (NNRTI) 

























Supplementary figure 1: Duration on ART in relation to number of thymidine analogue 












































Supplementary figure 2: Duration failing ART (viral load > 400 copies/ml) in relation to 






































Supplementary figure 3: Duration on ART in relation to number of non-nucleoside 










































Supplementary figure 4: Duration failing ART (viral load > 400 copies/ml) in relation to 
number of non-nucleoside reverse transcriptase inhibitor (NNRTI) mutations present 
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